We're thrilled to see siPOOLs being used increasingly by the research community.
Below, we highlight 3 latest publicationsin the field of cancer researchpublished by siPOOL users in Germany, Korea and the USA.
Visit our Publication Page for more publications with siPOOLs/raPOOLs.
Polycarpou-Schwarz, M., Groß, M., Mestdagh, P., Schott, J., Grund, S. E., Hildenbrand, C., Rom, J., Aulmann, S., Sinn, H.-P., Vandesompele, J., and Diederichs, S.The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene 2018
Small open reading frame (sORF)-encoded proteins or microproteins constitute a new class of molecules often transcribed from presumed long non-coding RNA transcripts (lncRNAs). Found in a variety of organisms, some carry out important biological functions, but many remain largely uncharacterized.
The authors identified and characterized a novel microprotein of 10 kDa highly expressed in breast cancer, named Cancer-Associated Small Integral Membrane Open reading frame 1 (CASIMO1).
So, D., Shin, H.-W., Kim, J., Lee, M., Myeong, J., Chun, Y.-S., and Park, J.-W. Cervical cancer is addicted to SIRT1 disarming the AIM2 antiviral defense. Oncogene 2018
Cervical cancer is largely caused by human papilloma virus (HPV) infection overcoming the host defense system.
Sirtuin 1 (SIRT1), more widely known for its role in longevity, was not only overexpressed in HPV-infected cervical cancer cells but also found necessary for cancer cell survival.
An interesting mechanism of SIRT1-mediated protection involved regulating extracellular vesicle transmission of the AIM2 inflammasome.
Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J. S., Brown, M., Aster, J. C., and Liu, X. S. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies. Cell Systems 2018
Identifying reliable drug response biomarkers is a significant challenge in cancer research.
The authors present computational analysis of resistance (CARE) to help predict therapy outcome and synergistic drug combinations.
CARE examines how the mutation or expression state of gene P interacts with drug target gene status T to influence drug inhibition efficacy in a multivariate linear model.